# A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies

> **NCT05669430** · PHASE1,PHASE2 · RECRUITING · sponsor: **GV20 Therapeutics** · enrollment: 365 (estimated)

## Conditions studied

- Solid Tumor, Adult
- Refractory Cancer
- Endometrial Carcinoma (EC)
- Squamous Head and Neck Carcinoma
- pMMR/MSS Adenocarcinoma of the Colon or Rectum
- Cutaneous Melanoma
- Non-Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** GV20-0251
- **BIOLOGICAL:** GV20-0251
- **BIOLOGICAL:** GV20-0251 and Pembrolizumab [KEYTRUDA®]
- **BIOLOGICAL:** GV20-0251 and Pembrolizumab [KEYTRUDA®]

## Key facts

- **NCT ID:** NCT05669430
- **Lead sponsor:** GV20 Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-23
- **Primary completion:** 2026-12-15
- **Final completion:** 2027-09-05
- **Target enrollment:** 365 (ESTIMATED)
- **Last updated:** 2025-02-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05669430

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05669430, "A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05669430. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*